PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro
Open accessAbstract
mTOR is an important therapeutic target in many types of cancers. In melanoma, the mTOR nonsynonymous mutation rate is up to 10.4%. However, mTOR inhibitors have shown limited effects in clinical trials of melanoma. Because mTOR mutations are distributed, not selecting patients with specific mTOR mutations may be the main reason for therapeutic failures. Our previous research found that mutations in the mTOR P2213S and S2215Y kinase domains resulted in gain-of-function and were sensitive to specific inhibitors. The purpose of this study was to test the effect of heterozygous/homozygous H2189Y mutations on downstream pathways and sensitivity to inhibitors. mTOR kinase activity was analyzed by western blot and a K-LISA™ mTOR activity kit. The sensitivity of melanoma cells to inhibitors was tested by a proliferation assay. The expression of downstream pathway proteins was also analyzed by western blot. The results showed that heterozygous/homozygous H2189Y mutations were gain-of-function. The heterozygous H2189Y mutation was sensitive to the AKT inhibitor, AZD5363, and the phosphoinositide 3-kinase inhibitor, LY294002. The homozygous H2189Y mutation was sensitive to the mTOR inhibitor, everolimus, and the AKT inhibitors AZD5363 and MK-2206 2HCL,and the phosphoinositide 3-kinase inhibitor, LY294002. These results indicated that homozygous mutations in the kinase domain have a greater effect on protein function than heterozygous mutations. The mTOR kinase domain may play an important role in mTOR kinase activity and may be the target of selective inhibitors. Our study can facilitate the selection of appropriate inhibitors for patients in clinical trials.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Although the mTOR pathway can be activated in the majority of melanomas, mTOR inhibitors have not been proven effective in this clinical setting.
“Although the mTOR pathway can be activated in the majority of melanomas, mTOR inhibitors have not been proven effective in this clinical setting20–22.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003 · see citing works
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · see citing works
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I. J., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,542 · see citing works
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,149 · see citing works
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · see citing works
TOR, a central controller of cell growth.
Schmelzle, T., & Hall, M. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 2,044 · see citing works
Čermák, T., Doyle, E., Christian, M. L., Wang, L., Zhang, Y., Schmidt, C. L., Baller, J. A., Somia, N. V., Bogdanove, A. J., & Voytas, D. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr218 · Cited by 2,034 · see citing works
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · see citing works
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330 · see citing works
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 930 · see citing works
KIT as a Therapeutic Target in Metastatic Melanoma
Carvajal, R. D. (2011) · JAMA · doi:10.1001/jama.2011.746 · Cited by 886 · see citing works
Sekulić, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., & Abraham, R. T. (2000) · PubMed · Cited by 712 · see citing works
Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., Corless, C. L., Li, L., Li, H., Sheng, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9275 · Cited by 685 · see citing works
Self-citationAkt activation by growth factors is a multiple-step process: the role of the PH domain
Bellacosa, A., Chan, T. O., Ahmed, N. N., Datta, K., Malstrom, S. E., Stokoe, D., McCormick, F. P., Feng, J., & Tsichlis, P. N. (1998) · Oncogene · doi:10.1038/sj.onc.1201947 · Cited by 548 · see citing works
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 480 · see citing works
Hu, L., Zaloudek, C. J., Mills, G. B., Gray, J. W., & Jaffe, R. B. (2000) · PubMed · Cited by 301 · see citing works
CCI‐779 in metastatic melanoma
Margolin, K. A., Longmate, J., Baratta, T., Synold, T. W., Christensen, S., Weber, J. S., Gajewski, T. F., Quirt, I. C., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 228 · see citing works
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 214 · see citing works
(2001) · PubMed · Cited by 193 · see citing works
Protein-structure-guided discovery of functional mutations across 19 cancer types
Niu, B., Scott, A. D., Sengupta, S., Bailey, M. H., Batra, P., Ning, J., Wyczalkowski, M. A., Liang, W.-W., Zhang, Q., McLellan, M. D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3586 · Cited by 137 · see citing works
Analysis of mTOR signaling by the small G‐proteins, Rheb and RhebL1
Tee, A. R., Blenis, J., & Proud, C. G. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.07.054 · Cited by 111 · see citing works
Targeting drivers of melanoma with synthetic small molecules and phytochemicals
Strickland, L. R., Pal, H. C., Elmets, C. A., & Afaq, F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.016 · Cited by 81 · see citing works
Kong, Y., Si, L., Li, Y., Wu, X., Xu, X., Dai, J., Tang, H., Ma, M., Chi, Z., Sheng, X., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1110 · Cited by 79 · see citing works
Self-citationMutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*
Murugan, A. K., Alzahrani, A. S., & Xing, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399485 · Cited by 45 · see citing works
Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma
Dronca, R. S., Allred, J. B., Pérez, D. G., et al. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31827b45d4 · Cited by 44 · see citing works
Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma
Rao, R. D., Windschitl, H. E., Allred, J. B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8043 · Cited by 35 · see citing works
Kurdi, A., Doncker, M. D., Leloup, A. J. A., Neels, H. M., Timmermans, J., Lemmens, K., Apers, S., Meyer, G. R. Y. D., & Martinet, W. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13626 · Cited by 25 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12628-1 · Cited by 109 · see citing works
- Authors
- Wu, X., Yu, J., Yan, J., Dai, J., Si, L., Chi, Z., Sheng, X., Cui, C., Ma, M., Tang, H., Xu, T., Yu, H., Kong, Y., & Guo, J.
- Affiliations
- Peking University Cancer Hospital (CN)
- Corresponding author
- Kong, Yan
- Guo, Jun
- ORCID
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-04-30
- Volume
- 19
- Issue
- 7
- Pages
- 584-589
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- PMC
- PMC5989792
- OpenAlex
- W2799744839
- Cited by
- 25
- References
- 28
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 2 · 2022: 5 · 2021: 2 · 2020: 5 · 2019: 3
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Biology & Therapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (NSFC) (81772912, 81672696)
- Major State Basic Research Development Program of China (2013CB911004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- melanoma, PI3K/AKT/mTOR pathway, mTOR inhibitors, everolimus, AZD5363, MK-2206, LY294002, AKT inhibitors, gain-of-function mutations, kinase domain, drug sensitivity, patient selection
- MeSH terms
- Protein Domains, Phosphoinositide-3 Kinase Inhibitors, Animals, Humans, Melanoma, Mice, Nude, Skin Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Mutation, Missense, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Proto-Oncogene Proteins c-akt, Mice, HEK293 Cells, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
